Search

Your search keyword '"MULDER, B."' showing total 1,318 results
Start Over Author "MULDER, B."
1,318 results on '"MULDER, B."'

102. European society of cardiology

Author

Timmis, Adam, Townsend, Nick, Gale, Chris P., Torbica, Aleksandra, Lettino, Maddalena, Petersen, Steffen E., Mossialos, Elias A., Maggioni, Aldo P., Kazakiewicz, Dzianis, May, Heidi T, De Smedt, Delphine, Flather, Marcus, Zuhlke, Liesl, Beltrame, John F., Huculeci, Radu, Tavazzi, Luigi, Hindricks, Gerhard, Bax, Jeroen, Casadei, Barbara, Achenbach, Stephan, Wright, Lucy, Vardas, Panos, Mimoza, Lezha, Artan, Goda, Aurel, Demiraj, Chettibi, Mohammed, Hammoudi, Naima, Sisakian, Hamayak, Pepoyan, Sergey, Metzler, Bernhard, Siostrzonek, Peter, Weidinger, Franz, Jahangirov, Tofig, Aliyev, Farid, Rustamova, Yasmin, Manak, Nikolay, Mrochak, Aliaksandr, Lancellotti, Patrizio, Pasquet, Agnès, Claeys, Marc, Kušljugić, Zumreta, Dizdarević Hudić, Larisa, Smajić, Elnur, Tokmakova, Mariya Petkova, Gatzov, Plamen Marinov, Milicic, Davor, Bergovec, Mijo, Christou, Christos, Moustra, Hera Heracleous, Christodoulides, Theodoros, Linhart, Ales, Taborsky, Milos, Hansen, Henrik Steen, Holmvang, Lene, Kristensen, Steen Dalby, Abdelhamid, Magdy, Shokry, Khaled, Kampus, Priit, Viigimaa, Margus, Ryödi, Essi, Niemelä, Matti, Rissanen, Tuomas T., Le Heuzey, Jean-Yves, Gilard, Martine, Aladashvili, A., Gamkrelidze, A., Kereselidze, Maia, Zeiher, A., Katus, H., Bestehorn, K., Tsioufis, Costas, Goudevenos, John, Csanádi, Zoltán, Becker, Dávid, Tóth, Kálmán, Jóna Hrafnkelsdóttir, Þórdís, Crowley, James, Kearney, Peter, Dalton, Barbra, Zahger, Doron, Wolak, Arik, Gabrielli, Domenico, Indolfi, Ciro, Urbinati, Stefano, Imantayeva, Gulnara, Berkinbayev, Salim, Bajraktari, Gani, Ahmeti, Artan, Berisha, Gezim, Erkin, Mirrakhimov, Saamay, Abilova, Erglis, Andrejs, Bajare, Iveta, Jegere, Sanda, Mohammed, Malek, Sarkis, Antoine, Saadeh, Georges, Zvirblyte, Ruta, Sakalyte, Gintare, Slapikas, Rimvydas, Ellafi, Khaled, El Ghamari, Fathi, Banu, Cristiana, Beissel, Jean, Felice, Tiziana, Buttigieg, Sandra C, Xuereb, Robert G., Popovici, Mihail, Boskovic, Aneta, Rabrenovic, Miroslav, Ztot, Samir, Abir-khalil, Saadia, van Rossum, A. C., Mulder, B. J. M., Elsendoorn, M. W., Srbinovska-Kostovska, Elizabeta, Kostov, Jorgo, Marjan, Bosevski, Steigen, Terje, Mjølstad, Ole Christian, Ponikowski, Piotr, Witkowski, Adam, Jankowski, Piotr, Gil, Victor Machado, Mimoso, Jorge, Baptista, Sérgio, Vinereanu, Dragos, Chioncel, Ovidiu, Popescu, Bogdan A., Shlyakhto, Evgeny, Oganov, Raphael, Foscoli, Marina, Zavatta, Marco, Dikic, Ana Djordjevic, Beleslin, Branko, Radovanovic, Mina Radosavljevic, Hlivák, Peter, Hatala, Robert, Kaliská, Gabriela, Kenda, Miran, Fras, Zlatko, Anguita, Manuel, Cequier, Ángel, Muñiz, Javier, James, Stefan, Johansson, Bengt, Platonov, Pyotr, Zellweger, Michael Johannes, Pedrazzini, Giovanni B., Carballo, David, Shebli, Hussam Eddin, Kabbani, Samer, Abid, Leila, Addad, Faouzi, Bozkurt, Engin, Kayıkçıoğlu, Meral, Erol, Mustafa Kemal, Kovalenko, Volodymyr, Nesukay, Elena, Wragg, Andrew, Ludman, Peter, Ray, Simon, Kurbanov, Ravshanbek, Boateng, Dennis, Daval, Ghislain, De Benito Rubio, Víctor, Sebastiao, David, De Courtelary, Paola Thellung, Bardinet, Isabel, Cardiology, ACS - Heart failure & arrhythmias, APH - Personalized Medicine, and APH - Aging & Later Life

Subjects
Male, medicine.medical_specialty, Mortality • morbidity, Health infrastructure, Cardiology, Disease, 030204 cardiovascular system & hematology, European Society of Cardiology, 03 medical and health sciences, 0302 clinical medicine, CARDIOVASCULAR DISEASE, EUROPEAN SOCIETY OF CARDIOLOGY, HEALTH INFRASTRUCTURE, MORBIDITY, MORTALITY, RISK FACTORS, SERVICE PROVISION, STATISTICS, Interquartile range, Internal medicine, Statistics, medicine, Humans, 030212 general & internal medicine, Myocardial infarction, Service provision, Mortality, Disease burden, business.industry, medicine.disease, Cardiovascular disease, Obesity, Europe, Years of potential life lost, Risk factors, Cardiovascular Diseases, Hypertension, Income, Female, Population Risk, Morbidity, Cardiology and Cardiovascular Medicine, business, Body mass index
Abstract

Aims The 2019 report from the European Society of Cardiology (ESC) Atlas provides a contemporary analysis of cardiovascular disease (CVD) statistics across 56 member countries, with particular emphasis on international inequalities in disease burden and healthcare delivery together with estimates of progress towards meeting 2025 World Health Organization (WHO) non-communicable disease targets. Methods and results In this report, contemporary CVD statistics are presented for member countries of the ESC. The statistics are drawn from the ESC Atlas which is a repository of CVD data from a variety of sources including the WHO, the Institute for Health Metrics and Evaluation, and the World Bank. The Atlas also includes novel ESC sponsored data on human and capital infrastructure and cardiovascular healthcare delivery obtained by annual survey of the national societies of ESC member countries. Across ESC member countries, the prevalence of obesity (body mass index ≥30 kg/m2) and diabetes has increased two- to three-fold during the last 30 years making the WHO 2025 target to halt rises in these risk factors unlikely to be achieved. More encouraging have been variable declines in hypertension, smoking, and alcohol consumption but on current trends only the reduction in smoking from 28% to 21% during the last 20 years appears sufficient for the WHO target to be achieved. The median age-standardized prevalence of major risk factors was higher in middle-income compared with high-income ESC member countries for hypertension {23.8% [interquartile range (IQR) 22.5–23.1%] vs. 15.7% (IQR 14.5–21.1%)}, diabetes [7.7% (IQR 7.1–10.1%) vs. 5.6% (IQR 4.8–7.0%)], and among males smoking [43.8% (IQR 37.4–48.0%) vs. 26.0% (IQR 20.9–31.7%)] although among females smoking was less common in middle-income countries [8.7% (IQR 3.0–10.8) vs. 16.7% (IQR 13.9–19.7%)]. There were associated inequalities in disease burden with disability-adjusted life years per 100 000 people due to CVD over three times as high in middle-income [7160 (IQR 5655–8115)] compared with high-income [2235 (IQR 1896–3602)] countries. Cardiovascular disease mortality was also higher in middle-income countries where it accounted for a greater proportion of potential years of life lost compared with high-income countries in both females (43% vs. 28%) and males (39% vs. 28%). Despite the inequalities in disease burden across ESC member countries, survey data from the National Cardiac Societies of the ESC showed that middle-income member countries remain severely under-resourced compared with high-income countries in terms of cardiological person-power and technological infrastructure. Under-resourcing in middle-income countries is associated with a severe procedural deficit compared with high-income countries in terms of coronary intervention, device implantation and cardiac surgical procedures. Conclusion A seemingly inexorable rise in the prevalence of obesity and diabetes currently provides the greatest challenge to achieving further reductions in CVD burden across ESC member countries. Additional challenges are provided by inequalities in disease burden that now require intensification of policy initiatives in order to reduce population risk and prioritize cardiovascular healthcare delivery, particularly in the middle-income countries of the ESC where need is greatest.

Published
2020

103. Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial

Author

Andel, M.M. van, Indrakusuma, R., Jalalzadeh, H., Balm, R., Timmermans, J., Scholte, A.J., Berg, M.P., Zwinderman, A.H., Mulder, B. J. M., Waard, V. de, Groenink, M., Andel, M.M. van, Indrakusuma, R., Jalalzadeh, H., Balm, R., Timmermans, J., Scholte, A.J., Berg, M.P., Zwinderman, A.H., Mulder, B. J. M., Waard, V. de, and Groenink, M.

Abstract

Contains fulltext : 229174.pdf (Publisher’s version ) (Open Access), AIMS: The COMPARE trial showed a small but significant beneficial effect of 3-year losartan treatment on aortic root dilatation rate in adults with Marfan syndrome (MFS). However, no significant effect was found on clinical endpoints, possibly due to a short follow-up period. The aim of the current study was therefore to investigate the long-term clinical outcomes after losartan treatment. METHODS AND RESULTS: In the original COMPARE study (inclusion 2008-2009), adult patients with MFS (n = 233) were randomly allocated to either the angiotensin-II receptor blocker losartan® on top of regular treatment (β-blockers in 71% of the patients) or no additional medication. After the COMPARE trial period of 3 years, study subjects chose to continue their losartan medication or not. In a median follow-up period of 8 years, 75 patients continued losartan medication, whereas 78 patients, originally allocated to the control group, never used losartan after inclusion. No differences existed between baseline characteristics of the two groups except for age at inclusion [losartan 34 (interquartile range, IQR 26-43) years, control 41 (IQR 30-52) years; P = 0.031], and β-blocker use (losartan 81%, control 64%; P = 0.022). A pathological FBN1 mutation was present in 76% of patients and 58% of the patients were male. Clinical endpoints, defined as all-cause mortality, aortic dissection/rupture, elective aortic root replacement, reoperation, and vascular graft implantation beyond the aortic root, were compared between the two groups. A per-patient composite endpoint was also analysed. Five deaths, 14 aortic dissections, 23 aortic root replacements, 3 reoperations, and 3 vascular graft implantations beyond the aortic root occurred during follow-up. Except for aortic root replacement, all endpoints occurred in patients with an operated aortic root. Patients who used losartan during the entire follow-up period showed a reduced number of events compared to the control group (death: 0 vs. 5

Published
2020

104. Doppler gradients, valve area and ventricular function in pregnant women with aortic or pulmonary valve disease: Left versus right

Author

Siegmund, A.S., Pieper, P.G., Mulder, B. J. M., Sieswerda, G.T., Dijk, A.P. van, Roos-Hesselink, J.W., Veldhuisen, D.J. van, Aalberts, Jan J.J., Siegmund, A.S., Pieper, P.G., Mulder, B. J. M., Sieswerda, G.T., Dijk, A.P. van, Roos-Hesselink, J.W., Veldhuisen, D.J. van, and Aalberts, Jan J.J.

Abstract

Contains fulltext : 218094.pdf (Publisher’s version ) (Closed access)

Published
2020

105. Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide study

Author

Yang, H., Bouma, B.J., Dimopoulos, K., Khairy, P., Ladouceur, M., Niwa, K., Dijk, A.P. van, Aboulhosn, J., Mulder, B. J. M., Yang, H., Bouma, B.J., Dimopoulos, K., Khairy, P., Ladouceur, M., Niwa, K., Dijk, A.P. van, Aboulhosn, J., and Mulder, B. J. M.

Abstract

Contains fulltext : 214082.pdf (Publisher’s version ) (Open Access)

Published
2020

106. New developments in adult congenital heart disease

Author

Bouma, B.J., Sieswerda, G.T., Post, M.C., Ebels, T., Kimmenade, R.R. van, Winter, R.J. de, Mulder, B. J. M., Bouma, B.J., Sieswerda, G.T., Post, M.C., Ebels, T., Kimmenade, R.R. van, Winter, R.J. de, and Mulder, B. J. M.

Abstract

Contains fulltext : 225482.pdf (Publisher’s version ) (Open Access), Congenital heart disease (CHD) affects 0.8% of live births and over the past decades technical improvements and large-scale repair has led to increased survival into adulthood of over 95% of the new-born. A new group of patients, those who survived their congenital heart defect, has emerged but late complications including heart failure, pulmonary hypertension (PH), arrhythmias, aneurysms and endocarditis appeared numerous, with a huge impact on mortality and morbidity. However, innovations over the past years have changed the landscape of adult CHD dramatically. In the diagnostic process important improvements have been made in the use of MRI, biomarkers, e‑health concepts and 3D visualisation of anatomy. Care is now concentrated in specialised centres, with a continuous emphasis on education and the introduction of weekly multidisciplinary consultations on diagnosis and intervention. Surgery and percutaneous intervention have been refined and new concepts applied, further reducing the burden of the congenital malformations. Research has matured from case series to global networks. Currently, adults with CHD are still facing high risks of early mortality and morbidity. By global collaboration and continuous education and development and innovation of our diagnostic and therapeutic arsenal, we will improve the perspectives of these young patients.

Published
2020

107. Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease?: Results of a worldwide study

Author

Team Medisch, UMC Utrecht, Circulatory Health, Yang, H., Bouma, B. J., Dimopoulos, K., Khairy, P., Ladouceur, M., Niwa, K., Greutmann, M., Schwerzmann, M., Egbe, A., Scognamiglio, G., Budts, W., Veldtman, G., Opotowsky, A. R., Broberg, C. S., Gumbiene, L., Meijboom, F. J., Rutz, T., Post, M. C., Moe, T., Lipczyńska, M., Tsai, S. F., Chakrabarti, S., Tobler, D., Davidson, W., Morissens, M., van Dijk, A., Buber, J., Bouchardy, J., Skoglund, K., Christersson, C., Kronvall, T., Konings, T. C., Alonso-Gonzalez, R., Mizuno, A., Webb, G., Laukyte, M., Sieswerda, G. T.J., Shafer, K., Aboulhosn, J., Mulder, B. J.M., Team Medisch, UMC Utrecht, Circulatory Health, Yang, H., Bouma, B. J., Dimopoulos, K., Khairy, P., Ladouceur, M., Niwa, K., Greutmann, M., Schwerzmann, M., Egbe, A., Scognamiglio, G., Budts, W., Veldtman, G., Opotowsky, A. R., Broberg, C. S., Gumbiene, L., Meijboom, F. J., Rutz, T., Post, M. C., Moe, T., Lipczyńska, M., Tsai, S. F., Chakrabarti, S., Tobler, D., Davidson, W., Morissens, M., van Dijk, A., Buber, J., Bouchardy, J., Skoglund, K., Christersson, C., Kronvall, T., Konings, T. C., Alonso-Gonzalez, R., Mizuno, A., Webb, G., Laukyte, M., Sieswerda, G. T.J., Shafer, K., Aboulhosn, J., and Mulder, B. J.M.

Published
2020

108. International consensus:Ovarian tissue cryopreservation in young Turner syndrome patients: Outcomes of an ethical Delphi study including 55 experts from 16 different countries

Author

Schleedoorn, M. J., Mulder, B. H., Braat, D. D.M., Beerendonk, C. C.M., Peek, R., Nelen, W. L.D.M., van Leeuwen, E., van der Velden, A. A.E.M., Fleischer, K., Schleedoorn, M. J., Mulder, B. H., Braat, D. D.M., Beerendonk, C. C.M., Peek, R., Nelen, W. L.D.M., van Leeuwen, E., van der Velden, A. A.E.M., and Fleischer, K.

Abstract

STUDY QUESTION: What is the standpoint of an international expert panel on ovarian tissue cryopreservation (OTC) in young females with Turner syndrome (TS)? SUMMARY ANSWER: The expert panel states that OTC should be offered to young females with TS, but under strict conditions only. WHAT IS KNOWN ALREADY: OTC is already an option for preserving the fertility of young females at risk of iatrogenic primary ovarian insufficiency (POI). Offering OTC to females with a genetic cause of POI could be the next step. One of the most common genetic disorders related to POI is TS. Due to an early depletion of the ovarian reserve, most females with TS are confronted with infertility before reaching adulthood. However, before offering OTC as an experimental fertility preservation option to young females with TS, medical and ethical concerns need to be addressed. STUDY DESIGN, SIZE, DURATION: A three-round ethical Delphi study was conducted to systematically discuss whether the expected benefits exceed the expected negative consequences of OTC in young females with TS. The aim was to reach group consensus and form an international standpoint based on selected key statements. The study took place between February and December 2018. PARTICIPANTS/MATERIALS, SETTING, METHODS: Anonymous panel selection was based on expertise in TS, fertility preservation or medical ethics. A mixed panel of 12 gynaecologists, 13 (paediatric) endocrinologists, 10 medical ethicists and 20 patient representatives from 16 different countries gave consent to participate in this international Delphi study. In the first two rounds, experts were asked to rate and rank 38 statements regarding OTC in females with TS. Participants were offered the possibility to adjust their opinions after repetitive feedback. The selection of key statements was based on strict inclusion criteria. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 46 participants completed the first Delphi round (response rate 84%). Based on stric

Published
2020

109. Preoperative Predictors of Death and Sustained Ventricular Tachycardia After Pulmonary Valve Replacement in Patients With Repaired Tetralogy of Fallot Enrolled in the INDICATOR Cohort

Author

Geva, T, Mulder, B, Gavreau, K, Babu-Narayan, SV, Wald, MD, Gatzoulis, M, Valente, AM, Hickey, K, Powell, AJ, Gatzoulis, MA, British Heart Foundation, Cardiology, APH - Personalized Medicine, APH - Aging & Later Life, and ACS - Heart failure & arrhythmias

Subjects
Male, Tachycardia, Time Factors, Cardiac & Cardiovascular Systems, Ventricular Dysfunction, Right, MULTICENTER, 030204 cardiovascular system & hematology, REGURGITATION, tachycardia, Muscle hypertrophy, Electrocardiography, 0302 clinical medicine, Pulmonary Valve Replacement, MAGNETIC-RESONANCE, risk factors, Registries, 030212 general & internal medicine, tetralogy of Fallot, 1102 Cardiorespiratory Medicine and Haematology, Tetralogy of Fallot, ALL-CAUSE MORTALITY, Heart Valve Prosthesis Implantation, OUTCOMES, medicine.diagnostic_test, ARRHYTHMIA, ASSOCIATION, Middle Aged, Magnetic Resonance Imaging, Echocardiography, Doppler, Pulmonary Valve Stenosis, ventricular, medicine.anatomical_structure, Cohort, Cardiology, cardiovascular system, Female, medicine.symptom, Cardiology and Cardiovascular Medicine, hypertrophy, Life Sciences & Biomedicine, tachycardia, ventricular, Adult, medicine.medical_specialty, Adolescent, Regurgitation (circulation), Risk Assessment, 1117 Public Health and Health Services, Young Adult, 03 medical and health sciences, pulmonary valve, Physiology (medical), Internal medicine, medicine, Humans, cardiovascular diseases, Cardiac Surgical Procedures, right ventricular, Science & Technology, business.industry, Hemodynamics, LONG-TERM SURVIVAL, Magnetic resonance imaging, 1103 Clinical Sciences, ADULTS, hypertrophy, right ventricular, medicine.disease, eye diseases, Peripheral Vascular Disease, Cardiovascular System & Hematology, Pulmonary valve, Ventricular Function, Right, Cardiovascular System & Cardiology, treatment outcome, RISK-FACTORS, sense organs, business
Abstract

Background: Risk factors for adverse clinical outcomes have been identified in patients with repaired tetralogy of Fallot before pulmonary valve replacement (PVR). However, pre-PVR predictors for post-PVR sustained ventricular tachycardia and death have not been identified. Methods: Patients with repaired tetralogy of Fallot enrolled in the INDICATOR cohort (International Multicenter TOF Registry), a 4-center international cohort study, who had a comprehensive preoperative evaluation and subsequently underwent PVR were included. Preprocedural clinical, ECG, cardiovascular magnetic resonance, and postoperative outcome data were analyzed. Cox proportional hazards multivariable regression analysis was used to evaluate factors associated with time from pre-PVR cardiovascular magnetic resonance until the primary outcome: death, aborted sudden cardiac death, or sustained ventricular tachycardia. Results: Of the 452 eligible patients (median age at PVR, 25.8 years), 36 (8%) reached the primary outcome (27 deaths, 2 resuscitated death, and 7 sustained ventricular tachycardia) at a median time after PVR of 6.5 years. Cox proportional hazards regression identified pre-PVR right ventricular ejection fraction P =0.02), right ventricular mass-to-volume ratio ≥0.45 g/mL (hazard ratio, 4.08; 95% CI, 1.57–10.6; P =0.004), and age at PVR ≥28 years (hazard ratio, 3.10; 95% CI, 1.42–6.78; P =0.005) as outcome predictors. In a subgroup analysis of 230 patients with Doppler data, predicted right ventricular systolic pressure ≥40 mm Hg was associated with the primary outcome (hazard ratio, 3.42; 95% CI, 1.09–10.7; P =0.04). Preoperative predictors of a composite secondary outcome, postoperative arrhythmias and heart failure, included older age at PVR, pre-PVR atrial tachyarrhythmias, and a higher left ventricular end-systolic volume index. Conclusions: In this observational investigation of patients with repaired tetralogy of Fallot, an older age at PVR and pre-PVR right ventricular hypertrophy and dysfunction were predictive of a shorter time to postoperative death and sustained ventricular tachycardia. These findings may inform the timing of PVR if confirmed by prospective clinical trials.

Published
2018
Full Text
View/download PDF

112. Studying collisions in the general physics laboratory with quadrature light emitting diode sensors

Author

DeYoung, P.A. and Mulder, B.

Subjects
Collisions (Physics) -- Research, Light-emitting diodes -- Usage, Optical detectors -- Usage, Physics
Abstract

We have developed the means to measure position rapidly and precisely as a function of time in the general physics laboratory. These measurements are of sufficient quality that velocities and accelerations can be calculated from the position data using numerical derivatives. The precision of the measurements is such that any disagreement between theoretical expectations and experimental measurements is less than a few percent. Measurements of the system under study can be made as rapidly as every 200 [micro]s, which is faster than the typical time scales over which the system changes. Measuring rapidly also allows one to investigate additional phenomena not previously accessible and to see features of the physics previously unobserved. The measurement system is based on commercially available sensors, computer hardware, and computer software (LABVIEW[TM]). Many general physics laboratories based on this system have been developed but only an investigation of Newton's second law will be described here.

Published
2002

115. 44 Aangeboren hartziekten

Author

Mulder, B. J. M., primary, Gewillig, M., additional, Pieper, P. G., additional, Meijboom, F. J., additional, Witsenburg, M., additional, and Hamer, J. P. M., additional

Published
2008
Full Text
View/download PDF

126. Therapie van parasitaire infecties in nederland

Author

Stelma, F.F., Hellemond, J. van, Genderen, P. van, Gool, T. van, Hekker, T., Kortbeek, T., Mank, T., Mulder, B., Visser, L de, and Sauerwein, R.W.

Subjects
lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]
Abstract

Item does not contain fulltext

Published
2017

136. Inleiding

Author

Mulder, Barbara, Mulder, B. J. M., Cardiology, APH - Personalized Medicine, APH - Aging & Later Life, Amsterdam Cardiovascular Sciences, and ACS - Heart failure & arrhythmias

Published
2019

138. Ebstein-malformatie van de tricuspidalisklep

Author

van Dijk, Arie, Robbers-Visser, Danielle, Bouma, Berto, Mulder, B. J. M., Cardiology, ACS - Heart failure & arrhythmias, and ACS - Pulmonary hypertension & thrombosis

Published
2019

139. Psychosociale problematiek

Author

Utens, Elisabeth, van Melle, J. P., Mulder, B. J. M., and Child Psychiatry

Published
2019

140. Transpositie van de grote arteriën

Author

van den Bosch, Annemien, van Kimmenade, Roland R. J., Bouma, Berto, Mulder, B. J. M., ACS - Heart failure & arrhythmias, ACS - Pulmonary hypertension & thrombosis, and Cardiology

Published
2019

141. Het Marfan-syndroom en andere aortopathieën

Author

Groenink, Maarten, Koolbergen, David, Mulder, Barbara, Mulder, B. J. M., ACS - Heart failure & arrhythmias, Cardiology, Cardiothoracic Surgery, APH - Personalized Medicine, and APH - Aging & Later Life

Published
2019

142. Ventrikelseptumdefect

Author

Robbers-Visser, Danielle, Hoendermis, Elke S., Mulder, Barbara, Mulder, B. J. M., Cardiology, APH - Personalized Medicine, APH - Aging & Later Life, Amsterdam Cardiovascular Sciences, and ACS - Heart failure & arrhythmias

Published
2019

143. Transitie van jongvolwassenen

Author

Moons, Philip, Robbers-Visser, Danielle, Meijboom, Folkert J., Mulder, B. J. M., Cardiology, and ACS - Heart failure & arrhythmias

Published
2019

145. Coarctatio aortae

Author

de Winter, Robbert, Hazekamp, Mark G., Pieper, Petronella G., Mulder, B. J. M., ACS - Heart failure & arrhythmias, Cardiology, and ACS - Atherosclerosis & ischemic syndromes

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results